Medscape

Budesonide/Formoterol pMDI Inhaler Reduces COPD Exacerbations

December 29, 2011 — A budesonide/formoterol pressurized metered dose inhaler (pMDI) reduced chronic obstructive pulmonary disease (COPD) exacerbations more effectively than a formoterol dry powder ...
Medscape

Rapid, Sustained Improvement in Airflow With Budesonide/Formoterol for COPD

November 19, 2009 (Miami, Florida) — The long-acting beta-agonist bronchodilator formoterol, administered alone or with the corticosteroid budesonide (BD/FM) through a pressurized metered-dose inhaler ...
clinicaladvisor.com

COPD exacerbations reduced with budesonide/formoterol treatment

Budesonide/formoterol treatment decreased COPD exacerbations Budesonide/formoterol treatment decreased exacerbations in COPD after 3 months. Patients with moderate-to-very-severe chronic obstructive ...
Healio

Triple inhaled therapy reduces moderate, severe COPD exacerbations: ETHOS

Please provide your email address to receive an email when new articles are posted on . Triple inhaled therapy with twice-daily budesonide, at two doses, glycopyrrolate and formoterol reduced the rate ...
Business Wire

GSK presents positive results from phase III FULFIL study of closed triple combination therapy FF/UMEC/VI versus Symbicort® Turbohaler® in COPD at ERS ... - Business Wire

This benefit of treatment with closed triple therapy was also observed in the subset of patients who received treatment for up to 52 weeks, with a statistically significant improvement of 179mL in ...
MedPage Today

Environmentally Friendlier COPD Inhaler May Also Be More Effective

There was a notable gap in effectiveness between metered-dose and dry-powder formulations of single-inhaler triple therapy for chronic obstructive pulmonary disease (COPD), according to real-world ...
MedPage Today

Triple Treatment Reduces COPD Exacerbations

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Inhaled triple ...
clinicaladvisor.com

Reduced All-Cause Mortality in COPD With Budesonide/ Glycopyrrolate/ Formoterol

Triple therapy with budesonide/glycopyrrolate/formoterol fumarate may reduce the risk of death compared with glycopyrrolate/formoterol fumarate in patients with COPD ...
Healio

FDA approves first generic of Symbicort for asthma, COPD

Please provide your email address to receive an email when new articles are posted on . The FDA announced approval of the first generic of Symbicort — budesonide and formoterol fumarate dihydrate — ...
PharmiWeb

Teva UK launches GoResp® Digihaler® (budesonide/ formoterol), the first integrated digital inhaler system for appropriate adult patients with asthma and COPD[i] in the UK

Castleford, UK Thursday 20 th July 2023 - Teva UK Limited today launched GoResp ® Digihaler ® i (budesonide / formoterol fumarate dihydrate) in the UK - the first country in Europe to make this ...
Nasdaq

AstraZeneca announces initiation of THARROS – a Phase III clinical trial investigating the potential of BREZTRI to improve cardiopulmonary outcomes in people with COPD

THARROS is the first-ever prospective trial to investigate the potential of an inhaled triple therapy to reduce cardiopulmonary events, a key driver of mortality, in COPD First patients dosed in ...